Piramal Pharma ko ₹136 Cr ka Consolidated Loss, Kenalog® Brand Khareeda

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Piramal Pharma ko ₹136 Cr ka Consolidated Loss, Kenalog® Brand Khareeda
Overview

Piramal Pharma ne Q3 FY26 mein ₹136.19 Cr ka consolidated net loss report kiya, jo last year ke profit se kaafi alag hai. Revenue bhi gira. Company ne Kenalog® brand ko acquire karne ki announcement ki hai.

📉 Financial Overview

The Numbers: Piramal Pharma Limited ne Q3 FY26 mein standalone aur consolidated dono mein mixed performance dikhaya. Standalone revenue 4.20% YoY kam hokar ₹1,195.81 Cr raha. Lekin, standalone Profit Before Tax (PBT) 14.09% YoY badhkar ₹181.87 Cr ho gaya, jiske baad exceptional item ko adjust karke ₹154.93 Cr (2.81% YoY down) raha. Standalone Net Profit After Tax (PAT) 8.51% YoY badhkar ₹128.91 Cr raha, jisme Basic EPS ₹0.97 tha.

Nine months ended December 31, 2025 (9M FY26) ke liye, standalone revenue 8.42% YoY kam hokar ₹3,292.95 Cr raha, jabki PAT 5.86% YoY badhkar ₹438.38 Cr raha.

Iske bilkul vipreet, consolidated revenue Q3 FY26 mein 2.92% YoY kam hokar ₹2,139.87 Cr raha. Company ne ₹136.19 Cr ka substantial net loss report kiya, jo pichhle saal is period mein ₹3.68 Cr ke net profit se bilkul alag hai. Isse Basic EPS -₹1.03 ho gaya. Consolidated net loss 9M FY26 mein badhkar ₹317.11 Cr ho gaya, jo 9M FY25 mein ₹62.37 Cr tha.

Quality Factor: Consolidated results par Q3 FY26 mein ₹41.11 Cr ke exceptional items ka bada asar pada. Isme ₹26.94 Cr new Labour Codes ke liye the aur £1,250,000 (₹14.60 Cr) ka one-time settlement UK subsidiary dwara kiya gaya tha. Standalone entity ke profit ke bawajood, consolidated profit se loss mein shift hona group ki broader structure mein operational ya financial challenges ko dikhata hai.

The Grill: Financial results ke saath management ki taraf se koi specific forward-looking guidance ya outlook par commentary nahi thi. Isse investors ko future performance ya strategic direction ka clear idea nahi mil paya.

🚩 Risks & Outlook

Company ka immediate outlook consolidated net loss aur declining revenues se overshadowed hai. Sabse bada risk hai Kenalog® brand ka Bristol-Myers Squibb se acquisition, jisme USD 35 million (₹314.58 Cr) upfront payment aur USD 65 million (₹584.22 Cr) tak ka contingent consideration shamil hai. Yeh ek significant financial commitment hai. Investors closely look karenge ki yeh acquisition future earnings, debt levels aur market positioning ko kaise affect karta hai. Consolidated results mein dikhai gayi challenges operational efficiency ya market competitiveness mein potential headwinds suggest karti hain jinhe address karna hoga. Guidance ki kami uncertainty ko aur badhati hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.